AMLX
AMLX
US03237H1014
Amylyx Pharmaceuticals, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- 87.371.000
--
Cost of Revenue -- 124.633.000
--
Gross Profit -- -37.262.000
--
153.291.000 218.415.000
29.8%
Operating Income -153.291.000 -255.677.000
40.0%
Pretax Income -144.689.000 -302.136.000
52.1%
Net Income Common Stockholders -144.735.000 -301.743.000
52.0%
-- --
--
-- --
--
ende